| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12220594 | IVR | 12000 mg/L | 12000 mg/L | Delayed puberty | Reproductive endocrine-mediated perturbations |
| IVR | 12000 mg/L | 12000 mg/L | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 12000 mg/L | 12000 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 12000 mg/L | 12000 mg/L | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 12000 mg/L | 12000 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 12000 mg/L | 12000 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| PMID:1909817 | IVR | 500 mg/L | 500 mg/L | Azoospermic | Reproductive endocrine-mediated perturbations |
| IVR | 500 mg/L | 500 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Alters hypothalamic-pituitary-gonadal axis (HPG axis) | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| PMID:22806249 | IVR | 2000 mg/L | 2000 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 2000 mg/L | 2000 mg/L | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 2000 mg/L | 2000 mg/L | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 2000 mg/L | 2000 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:25434758 | IVR | 0.05 % | 0.05 % | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations |
| IVR | 0.05 % | 0.05 % | Affects glycogen metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 % | 0.2 % | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 % | 0.2 % | Affects glycogen metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:7444965 | IVR | 250 mg/L | 250 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations |
| IVR | 250 mg/L | 250 mg/L | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 5 mg/L | - | No significant effects observed | - | |
| IVR | 0.5 mg/L | - | No significant effects observed | - | |
| IVR | 50 mg/L | 50 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 25 mg/L | 25 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:8199261 | IVR | 0.1 - 0.6 % | 0.1 - 0.6 % | Increased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 - 0.6 % | 0.1 - 0.6 % | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:8619245 | IVR | 0.6 % | 0.6 % | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.6 % | 0.6 % | Decreased weights of accessory sex organs | Reproductive endocrine-mediated perturbations | |
| IVR | 0.6 % | 0.6 % | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.6 % | 0.6 % | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:8989890 | IVR | 3500 mg/L | 3500 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| IVR | 5500 mg/L | 5500 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 5500 mg/L | 5500 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1500 mg/L | - | No significant effects observed | - |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.